3 Health Care Stocks Nudging The Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 57 points (0.3%) at 16,611 as of Monday, Aug. 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,452 issues advancing vs. 535 declining with 124 unchanged.

The Health Care sector currently sits up 1.1% versus the S&P 500, which is up 0.6%. Top gainers within the sector include Alnylam Pharmaceuticals ( ALNY), up 3.5%, ResMed ( RMD), up 2.3%, Incyte ( INCY), up 2.1%, Smith & Nephew ( SNN), up 2.1% and Pharmacyclics ( PCYC), up 1.9%. On the negative front, top decliners within the sector include Allergan ( AGN), down 2.2%, Illumina ( ILMN), down 2.1%, HCA Holdings ( HCA), down 1.0%, Aetna ( AET), down 0.9% and Mylan ( MYL), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Eli Lilly and ( LLY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Eli Lilly and is up $0.46 (0.8%) to $61.44 on light volume. Thus far, 1.4 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $61.10-$61.87 after having opened the day at $61.35 as compared to the previous trading day's close of $60.98.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $67.4 billion and is part of the drugs industry. Shares are up 18.3% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Shire ( SHPG) is up $4.66 (2.0%) to $240.06 on light volume. Thus far, 461,803 shares of Shire exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $236.79-$240.78 after having opened the day at $237.07 as compared to the previous trading day's close of $235.40.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $45.6 billion and is part of the drugs industry. Shares are up 64.2% year-to-date as of the close of trading on Friday. Currently there are 4 analysts who rate Shire a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Shire Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is up $0.68 (1.3%) to $53.50 on average volume. Thus far, 5.0 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.4 million shares. The stock has ranged in price between $52.77-$53.60 after having opened the day at $53.00 as compared to the previous trading day's close of $52.82.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $83.4 billion and is part of the drugs industry. Shares are down 0.7% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full AbbVie Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists